Literature DB >> 6604033

Human T-cell leukemia virus type I: induction of syncytia and inhibition by patients' sera.

K Nagy, P Clapham, R Cheingsong-Popov, R A Weiss.   

Abstract

HTLV-producing T-cell lines induce cell fusion when co-cultivated with a wide variety of indicator cells, suggesting that HTLV envelope antigens interact with the membranes of many cell types. Serum antibodies from adult T-cell lymphoma-leukemia (ATL) patients inhibited the formation of syncytia, and sera from British, American and Japanese ATL patients inhibited cell fusion induced by American and Japanese HTLV isolates equally well. No serological cross-inhibition of syncytium induction was found between HTLV and bovine leukosis virus, Moloney murine leukemia virus and simian sarcoma-associated virus. A simple syncytium inhibition test in microtiter plates has been developed to provide a rapid screen for antibodies presumed to be specific to HTLV envelope glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604033     DOI: 10.1002/ijc.2910320310

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  60 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance.

Authors:  C Darcel
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

Review 3.  Structural and functional anatomy of the globular domain of complement protein C1q.

Authors:  Uday Kishore; Rohit Ghai; Trevor J Greenhough; Annette K Shrive; Domenico M Bonifati; Mihaela G Gadjeva; Patrick Waters; Mihaela S Kojouharova; Trinad Chakraborty; Alok Agrawal
Journal:  Immunol Lett       Date:  2004-09       Impact factor: 3.685

4.  New Approach for Inhibition of HIV Entry: Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives.

Authors:  Szilvia Kanizsai; József Ongrádi; János Aradi; Károly Nagy
Journal:  Pathol Oncol Res       Date:  2016-02-09       Impact factor: 3.201

5.  Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type I-mediated lymphocyte immortalization.

Authors:  J T Kimata; L Ratner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

6.  The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells.

Authors:  R Pozzatti; J Vogel; G Jay
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

7.  Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.

Authors:  Sarah I Daniels; Erin E Soule; Katharine S Davidoff; John G Bernbaum; Duosha Hu; Kenji Maeda; Stephen J Stahl; Nicole E Naiman; Abdul A Waheed; Eric O Freed; Paul Wingfield; Robert Yarchoan; David A Davis
Journal:  FASEB J       Date:  2013-10-04       Impact factor: 5.191

8.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

Authors:  M D Lairmore; A M DiGeorge; S F Conrad; A V Trevino; R B Lal; P T Kaumaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Pseudotypes of human T-cell leukemia virus types 1 and 2: neutralization by patients' sera.

Authors:  P Clapham; K Nagy; R A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

10.  Stimulation of virus production and induction of self-syncytium formation in human T-cell leukemia virus type I- and type II-infected T cells by 12-O-tetradecanoylphorbol-13-acetate.

Authors:  M Wolfson; M Lev; I Avinoah; Z Malik; M Löchelt; R M Flügel; A Dombrovski; M Aboud
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.